<DOC>
	<DOCNO>NCT01396213</DOCNO>
	<brief_summary>A randomized , double-blind , placebo-controlled Phase 2B study evaluate efficacy safety Larazotide Acetate treatment patient celiac disease persistent symptom despite gluten-free diet .</brief_summary>
	<brief_title>A Double-blind Placebo-controlled Study Evaluate Larazotide Acetate Treatment Celiac Disease</brief_title>
	<detailed_description>This double-blind , placebo-controlled Phase 2B study evaluate efficacy safety three different dos ( 0.5 , 1 2 mg TID ) Larazotide Acetate adjunct gluten-free diet treatment patient celiac disease ( CD ) . The diagnosis CD must establish jejunal biopsy well serology point time prior entry study . Patients must symptoms despite gluten-free diet define celiac disease domain gastrointestinal symptom rating scale equal 2.0 .</detailed_description>
	<mesh_term>Celiac Disease</mesh_term>
	<criteria>Inclusion Criteria ( select criterion , inclusive ) : biopsy proven serologyconfirmed celiac disease ( point time prior study entry ) write informed consent age 1875 BMI 18.540 symptom despite glutenfree diet ( diarrhea , nausea , stomach pain , bloat ) must attempt glutenfree diet least 12 month CeDGSRS score measurable serology Exclusion Criteria ( select criterion , allinclusive ) : Refractory celiac disease diagnose chronic active GI disease , irritable bowel syndrome , inflammatory bowel disease etc . severe complication celiac disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>celiac disease</keyword>
	<keyword>gastrointestinal symptom</keyword>
	<keyword>gluten-free diet</keyword>
	<keyword>patient biopsy-proven celiac disease symptom</keyword>
</DOC>